Skip to NavigationSkip to content

deal

Amgen drops $2.7bn to acquire stake in Chinese biotech in bid to expand in the region

Amgen has signed an agreement with Chinese biotech BeiGene to acquire a 20.5% stake in the latter, in a bid to “significantly accelerate” the pharma firm’s plans to “expand its oncology presence in China, the world's second-largest pharmaceutical market”, it has emerged.

Under the terms of the deal, Amgen will purchase the stake for $2.7 billion in cash, equivalent to $174.85 per share.

Gilead buys Novartis' herpes, flu and cold virus preclinical programmes

Gilead has acquired the rights to three of Novartis’ preclinical antiviral programmes, including investigational compounds with the potential to treat influenza, herpes and human rhinovirus, the virus that causes the common cold.

The deal will see Gilead acquire the exclusive global rights to develop and commercialise novel small molecules against the three undisclosed targets.

The deal will see Novartis receive an upfront payment of an undisclosed amount and up to $291 million in milestone payments on reaching commercial and developmental milestones.

Gilead invests $5.1 billion into Galapagos NV

Gilead has entered into a 10 year partnership with Belgo-Dutch biotech Galapagos NV.

The collaboration will see Gilead invest $5.1 billion in Galapagos. The deal will give Gilead access to Galapagos’ portfolio which includes six molecules in clinical trials, 20 preclinical programmes and a proven drug discovery platform.

Gilead will pay Galapagos $3.95 billion upfront and a further $1.1 billion equity investment which Galapagos will use to expand and accelerate its research and development programmes.

MSD buys Peloton Therapeutics in deal worth $2.1 billion

MSD has agreed to acquire all outstanding shares in Peloton Therapeutics in a deal worth up to $2.1 billion.

US firm MSD will pay Texas-based biotech Peloton Therapeutics $1 billion upfront and a further $1.15 billion based on the achievement of regulatory and sales milestones.

The acquisition comes as MSD seeks to boost its oncology pipeline with the addition of Peloton’s lead candidate cancer drug PT2977.

Takeda completes Shire acquisition

Japanese firm Takeda Pharmaceuticals has successfully completed its acquisition of Shire Plc. The long anticipated deal has propelled the firm into the top ten biggest pharmaceutical companies worldwide.

The $60 billion takeover is expected to nearly double Takeda’s annual consolidated sales to $31.3 billion. With an expanded global reach, Takeda now holds leading positions in both the US and Japan. The company will retain its focus on Oncology, GI, Neuroscience, Rare Diseases and PDT.

Taisho Pharma to buy Bristol-Myers Squibb's consumer health business in deal worth $1.6 bn

Japanese company Taisho Pharmaceuticals has offered Bristol-Myers Squibb $1.6 billion for its UPSA consumer health business.

With more than a century’s worth of experience, Taisho, the largest over-the-counter drugmaker in Japan, was established in 1912. The two companies have an established relationship with Taisho having purchased PT Squibb Indonesia from BMS in 2009.

Tech platform company WuXi Biologics inks deal with cancer specialist Oxford BioTherapeutics worth $450m

Clinical stage oncology firm Oxford BioTherapeutics has signed a deal with the open-access biologics technology platform company WuXi Biologics, in a deal worth more than $450 million.

The alliance has come as part of an effort to develop and commercialise five novel bispecific antibodies as treatments for several different cancers, through the use of WuXi Biologics WuXiBody Platform.

Boehringer signs $300 million deal with Epizyme over epigenetic cancer treatment

German firm Boehringer Ingelheim and the Massachusetts-based biotech Epizyme have announced that they will collaborate on the development of novel, small molecule, inhibitors directed toward two previously unaddressed epigenetic targets as potential therapies for people with cancer, in a deal worth up to $300 million.

AstraZeneca sells off three drugs in deal worth $350 million

Anglo-Swedish multinational AstraZeneca has agreed to sell the rights to three asthma and rhinitis drugs in a deal worth $350 million (£268 million).

The deal will see Swiss-headquartered and Luxembourg-listed firm Covis Pharma obtain rights to markets outside of the US as well as US royalties for all three medicines.

The sell-off has seen the company pursue a strategy of divestment and reinvestment as it develops new pipelines.

J&J buy global rights to Yuhan's lazertinib in deal worth $1.2bn

Johnson & Johnson’s Janssen Biotech unit has bought the rights to Yuhan's third-generation EGFR tyrosine kinase inhibitor (TKI) lazertinib in a deal worth up to $1.2 billion.

The deal will see J&J pay the South Korean firm $50 million upfront, while the company may pay $1.2 billion in total if commercial and developmental milestones are met. Double digit royalties on sales may also bolster Yuhan’s purse.

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches